Publication at Faculty of Medicine in Hradec Králové |
2010
Abstract
A complex treatment of diabetes mellitus type 2 is associated with prolongation of the human life, improvement of it quality and prevention of macro- and microvascular complications. Recent randomized clinical trials have shown evidence of benefit and safety of more intensive LDL cholesterol lowering in patients with diabetes and established cardiovascular disease supporting guidelines for a more intensive LDL goal of therapy.
Despite statin treatment, cardiovascular disease residual risk remains high. After LDL the next lipoprotein goal is to increase HDL.
The possible combinations include namely statin + fibrate, and further combination include fibrate + niacin, fibrate + ezetimibe, statin + niacin or + ezetimibe, or omega-3 fatty-acids.